Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer
Publisher
Springer New York
Reference51 articles.
1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5.
2. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989;86:2863–7.
3. Kimura S, Kasuya Y, Sawamura T, et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure–activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989;13 Suppl 5:S5–7.
4. Battistini B, D’Orleans-Juste P, Sirois P. Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600–28.
5. Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 1992;74:223–5.